Cairo – Mubasher: Minapharm Pharmaceuticals projected its consolidated revenues to increase to EGP 1.7 billion in 2018.
Cost of production is likely to double as a result to the increase in foreign-currency exchange rate, which may impact the company’s profitability, Minapharm added in a statement to the Egyptian Exchange (EGX) on Monday.
The company is expected to set up a new German-quality pharmaceutical factory with EGP 2.5 billion in investments within five to seven years.
Minapharm is planning to expand in the pharmaceutical industry through genetic engineering and next-generation therapy.
